Specsavers co-founder Mr Doug Perkins has made a special appearance to announce Australia and New Zealand’s top-performing practices, which received a medal named in his honour. Read more
AI-driven headset that detects AMD set for Australian debut
A US company that has incorporated dark adaptometry into a new wearable headset for age-related macular degeneration (AMD) is on the cusp of introducing the AI-guided technology to the Australian ophthalmic market. Read more
Aussie firm reveals next-gen MIGS device in pipeline
Adelaide ophthalmic device manufacturer Nova Eye Medical is developing a next generation iTrack glaucoma surgical system to reduce operating times. It is also progressing towards a pivotal US study for its 2RT laser therapy for intermediate AMD that could fulfil a distinct gap in a multi-billion-dollar market. Read more
Eyecare in a pandemic: counting the cost of missed appointments
The nation’s first comprehensive look at the impact of reduced optometry services due to the COVID-19 lockdown has been provided in new Specsavers data. Australia and New Zealand optometry director Dr BENJAMIN ASHBY delves into the statistics and outlines a plan to manage the patient backlog.
EssilorLuxottica weighs up appeal after GrandVision case dismissed
A Dutch court has dismissed a EssilorLuxottica court case demanding that its potential takeover target Grandvision disclose information over the way it conducted business during COVID-19, leaving the door open for an appeal. Read more
Opthea meets US and European regulators over Phase 3 trial
A Melbourne-based drug company is one step closer to starting Phase 3 clinical trials and pre-commercial development of its novel treatment for neovascular age-related macular degeneration (nAMD). Read more
TGA approves ‘breakthrough’ B+L contact lens
Bausch + Lomb has obtained regulatory approval to supply its new Ultra One Day daily disposable silicone hydrogel (SiHy daily) contact lenses in Australia. Read more
Eylea biosimilar embarks on Phase 3 trial
A biopharmaceutical company that is developing cheaper anti-VEGF treatments for Australia and other markets has launched a global clinical trial for a biosimilar version of leading treatment Eylea (aflibercept). Read more
Cylite’s HP-OCT secures ‘Australian Made’ status
Melbourne-based OCT manufacturer Cylite has obtained certification to carry the iconic Australian Made mark. Read more
New tech patents could signal disruption for retail eyewear
US tech giant Apple has filed a patent for a new head mounted device (HMD) that it claims can correct vision electronically when the device is worn. Read more